LHRH agonist

(redirected from Gonadotropin-releasing hormone agonist)
Also found in: Wikipedia.

Luteinizing hormone releasing hormone (LHRH) agonist

A substance that blocks the action of LHRH, a hormone that stimulates the production of testosterone (a male hormone) in men. Used to treat prostate cancers that require testosterone for growth.
Mentioned in: Prostate Cancer
References in periodicals archive ?
All patients underwent a long follicular gonadotropin-releasing hormone agonist (GnRHa) protocol.
Comparison of gonadotropin-releasing hormone agonist with GnRH antagonist in polycystic ovary syndrome patients undergoing in vitro fertilization cycle: Retrospective analysis from a tertiary center and review of literature.
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: Comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Effects of a gonadotropin-releasing hormone agonist implant on reproduction in a male marsupial, Macropus eugenii.
26) Several case reports using a gonadotropin-releasing hormone agonist as medical management for AAM showed complete radiographic resolution of the tumor.
The FDA is investigating whether treatment with a gonadotropin-releasing hormone agonist increases the risk of diabetes and cardiovascular events in men with prostate cancer.
Very similar results were seen in a series of 19 young women treated with leuprolide, a gonadotropin-releasing hormone agonist which is used in the management of uterine myomas.
Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
They therefore turned to a synthetic version of another naturally produced substance, called gonadotropin-releasing hormone agonist.
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Hormonal pattern and testicular histology in patients with prostatic cancer after long-term treatment with a gonadotropin-releasing hormone agonist analogue.
The researchers followed 119 patients who completed MRgFUS treatment for 12 months using phone interviews to assess symptomatic relief and any additional procedures for fibroid-related symptoms, including uterine embolization, myomectomy, hysterectomy, and gonadotropin-releasing hormone agonist treatment.

Full browser ?